PRO 140 is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of HIV infection.
PRO 140 is being developed by Progenics Pharmaceuticals. In May 2007, they announced results from the phase I clinical trial of the drug. The researchers said the results demonstrated "potent, rapid, prolonged, dose-dependent, highly significant antiviral activity" for PRO 140. Participants in the highest dosing group received 5mg/kg and showed a average viral load decrease of -1.83 log10. On average, reductions of greater than -1 log10 copies/ml were maintained for between two and three weeks, from only a single dose of the drug. The largest individual HIV RNA reductions ranged up to -2.5 log10 among patients receiving both the 2 and 5 mg/kg doses.
Mechanism of Action
PRO 140 functions as an entry inhibitor. PRO 140 binds to the CCR5 receptor, and interferes with HIV's ability to enter the cell. Unlike other entry inhibitors, PRO 140 is an monoclonal antibody. As such, it must be injected to be effective. However, once inside the body, PRO 140 binds to to CCR5 for >60 days, which may allow for dosing as infrequently as every other week.
- ↑ 1.0 1.1 Progenics Pharmaceuticals' HIV Drug, PRO 140, Receives FDA Fast-Track Designation. Press release, 22 Feb 2006. Progenics Pharmaceuticals.
- ↑ Brian Lawler. Progenics' Intriguing Study Results. The Motley Fool. 2 May 2007.
- ↑ Derek Thaczuk. ICAAC: Phase 1 study provides `proof of concept` for PRO 140, a monoclonal CCR5 antibody. AIDSmap.com. 21 Sept 2007.
- ↑ Liz Highleyman. Monoclonal Antibody CCR5 Inhibitor PRO 140 Produces Long-lasting HIV Suppression in Single-dose Study. 28 Sept 2007. HIVandHepatitis.com
- ↑ Biswas P, Tambussi G, Lazzarin A (2007). "Access denied? The status of co-receptor inhibition to counter HIV entry". Expert Opin Pharmacother 8 (7): 923–33. doi:10.1517/146565184.108.40.2063. PMID 17472538.
- ↑ PRO 140. Progenics Pharmaceuticals.
- ↑ Tim Horn. Single-Dose PRO 140 Has Lasting Effects. 21 Sept 2007. POZ.com.
Humanized monoclonal antibodies ("-zu-")
|"-tuzu-" (tumor)||Alemtuzumab, Bevacizumab/Ranibizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Dacetuzumab, Etaracizumab, Etaratuzumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab, Nimotuzumab, Pertuzumab, Sibrotuzumab, Sontuzumab, Tacatuzumab tetraxetan, Trastuzumab, Tucotuzumab celmoleukin|
|"-lizu-" (immune system)||Aselizumab, Atlizumab, Apolizumab, Cedelizumab, Certolizumab pegol, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Erlizumab, Fontolizumab, Ibalizumab, Lebrilizumab, Mepolizumab, Natalizumab, Ocrelizumab, Omalizumab, Pascolizumab, Pexelizumab, Reslizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Teplizumab, Tocilizumab, Toralizumab, Visilizumab|
|"-cizu-" (cardiovascular)||Bevacizumab, Tadocizumab|
|"-neuzu-" (nervous system)||Bapineuzumab|
|"-toxazu-" (toxin as target)||Urtoxazumab|
|"-vizu-" (viral infections)||Felvizumab, Motavizumab, Palivizumab, PRO 140|
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies